Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06745271 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made Available in the Body in Healthy Participants
A Phase 1 study, sponsored by Agios Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT06745271 is a Phase 1 study that has completed, run by Agios Pharmaceuticals. The registered enrollment target is 8 participants.
The verdict
NCT06745271, a Phase 1 study, has completed, sponsored by Agios Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine the routes, rates of elimination, mass balance of total radioactivity and metabolite profiles following a single oral dose of \[14C\]-tebapivat. To characterize the PK of tebapivat and \[13C2,15N3\]-tebapivat and determine the absolute bioavailability following single oral dose of \[14C\]-tebapivat relative to single intravenous microdose of \[13C2,15N3\]-tebapivat to healthy male participants.
Interventions
- DRUG [14C]-tebapivat
- DRUG [13C2,15N3]-tebapivat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2024-12-20 |
| Est. Completion | 2025-02-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06745271
The ClinicalTrials.gov registry entry for NCT06745271 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agios Pharmaceuticals, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which [14C]-tebapivat is the first listed.
NCT06745271 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06745271 about?
NCT06745271 is a clinical study titled "A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made Available in the Body in Healthy Participants". The primary purpose of this study is to determine the routes, rates of elimination, mass balance of total radioactivity and metabolite profiles following a single oral dose of \[14C\]-tebapivat. To characterize the PK of tebapivat and \[13C2,15N3\]-tebapivat and determine the absolute bioavailabilit...
What is the current status of trial NCT06745271?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2024-12-20. Estimated completion is 2025-02-21.
What interventions are being tested in trial NCT06745271?
The interventions under investigation include: [14C]-tebapivat (DRUG), [13C2,15N3]-tebapivat (DRUG).
Who is sponsoring clinical trial NCT06745271?
This trial is sponsored by Agios Pharmaceuticals, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.